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The rapid increase of antimicrobial resistance against conventional antibiotics has resulted in a signiﬁcant
focus on the use of peptides as antimicrobial agents. Understanding the structure and function
relationships of these compounds is thus highly important, however, their in vivo actions are a complex
issue, including interactions with small molecule agents. Here we report the folding inducing capability
of some pharmaceutical substances and synthetic dyes on the intrinsically disordered (ID) cationic
antimicrobial peptide CM15 (KWKLFKKIGAVLKVL). By employing circular dichroism (CD) spectroscopy, it
is shown that some therapeutic drugs (suramin, pamoic acid, cromolyn) and polysulfonated dyes (Congo
red, trypan blue) trigger the disorder-to-order conformational transition of CM15. The cooperative
binding of 2–4 acidic molecules per peptide chain provokes its folding in a concentration dependent
manner. Secondary structure analysis indicated the sharp and moderate rise of the a-helical and b-sheet
content, respectively. According to semi-empirical quantum chemical calculations, these organic
molecules may induce folding by forming multiple salt-bridges with lysine residues from both N- and
C-terminals as well as from the middle of the CM15 sequence. Due to the mutual neutralization of the
positive and negative charges, the water solubility of the resulting complexes decreases which favours
their aggregation as detected by dynamic light scattering measurements. Our ﬁndings suggest that small
molecules can dramatically aﬀect the structure of antimicrobial peptides, which may potentially alter,
either enhancing or attenuating, their eﬃciency. It is proposed that CM15 or similar ID peptides could be
useful for preliminary screening of folding inducer eﬀect of anionic drugs and biomolecules. The data
presented herein may stimulate further studies on the structural and functional impacts of related
compounds on ID peptides.Introduction
Cationic antimicrobial peptides (AMPs) are instrumental
constituents of the innate immune system and ubiquitous in all
living organisms.1 Their size typically ranges from 10 to 50
residues and most of them carry a net positive charge due to the
preponderance of lysine and arginine residues. The electrostatic
repulsion between these side chains renders the solution
structure of the majority of cationic AMPs intrinsically disor-
dered (ID) with no discernible secondary structure.2,3 However,
uponmembrane binding or in helix promoting organic solvents
such as triuoroethanol (TFE) many AMPs undergotute of Materials and Environmental
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hemistry 2017a conformational change and oen fold into a well ordered,
mostly a-helical structure.4,5 The membrane associated confor-
mational transition is a crucial step in mediating their biolog-
ical activities against a broad spectrum of bacteria, fungi,
parasites and even cancer cells.1 Besides the elimination and
inactivation of the invading pathogens, these multifaceted
substances also exhibit immunomodulatory activities.6 Impor-
tantly, disordered regions are characteristic not only to AMPs
but are highly abundant in eukaryotic proteomes as well.7 For
instance, about 60% of all proteins contain a disordered stretch
of 15 or more amino acids.8 Due to their exceptional structural
plasticity, intrinsically disordered proteins (IDPs) and ID
protein regions (IDPRs) are engaged in a plethora of biological
functions and thus in a variety of human diseases as well.9
Similarly to AMPs, their sequences are signicantly enriched in
charged (Arg, Lys, Glu, Asp) and other structure-breaking
residues.7,10
The natively unfolded CM15 is a synthetic hybrid peptide
containing ve cationic residues (Lys-Trp-Lys-Leu-Phe-Lys-Lys-
Ile-Gly-Ala-Val-Leu-Lys-Val-Leu).5,11–13 It is composed of the rstRSC Adv., 2017, 7, 41091–41097 | 41091
RSC Advances Paperseven amino acids of the insect AMP, cecropin A, and residues
2–9 of the bee venom peptide melittin (cecropin A (1–7)-melittin
(2–9)amide, CAS No. 157606-25-2). CM15 retains the bacteri-
cidal eﬀect of cecropins but lacks the hemolytic activity of
melittin. It is to be noted that cationic AMP families of human
and animal origins such as cathelicidins and NK-lysins abun-
dantly possess ID regions.14,15 Like CM15, NK-lysins are
amphiphilic and besides the disorder promoting Lys residues
they also contain some structure stabilizing aromatic side
chains (Trp, Phe).14 In addition, several examples of experi-
mentally veried ID protein regions are known consisting of
both order- and disorder promoting residues (ESI Table S1†).
From this point of view, CM15 can be considered as an, though
less typical, ID model sequence.
Employing experimental as well as computational methods,
our work demonstrates that some biologically active small
molecules deeply aﬀect the secondary structure of this peptide
inducing disorder-to-order conformational transition.
Materials and methods
Materials
Congo red sodium salt, trypan blue sodium salt, cromolyn
sodium salt, pamoic acid sodium salt and heparin sodium salt
(from porcine intestinal mucosa) were obtained from Sigma-
Aldrich and used as supplied. Suramin sodium salt was
purchased from Calbiochem. All other chemicals were of
analytical reagent grade.
Preparation of working solutions
All materials were dissolved in pH 7.3 potassium phosphate
buﬀer (10 mM) containing 50 mM Na2SO4. Due to its poly-
disperse nature, the molar concentration of heparin is expressed
in the average repeating disaccharide unit (Mwz 665).
Circular dichroism (CD) spectroscopic measurements
CD spectra were measured on a JASCO J-715 spectropolarimeter
at 25 0.2 C in a 0.1 cm path length rectangular quartz cuvette
(Hellma, USA). Temperature control was provided by a Peltier
thermostat. Peptide CD data were collected in continuous
scanning mode between 185 and 260 nm at a rate of 50 nm
min1, with a step size of 0.1 nm, response time of 4 s, three
accumulations, and 2 nm bandwidth. CD curves of peptide and
ligand–peptide samples were corrected by the spectral contri-
bution of the blank buﬀer solution. JASCO CD spec-
tropolarimeters record CD data as ellipticity (Q) in units of
millidegrees (mdeg). Q values were converted into molar
circular dichroic absorption per residues (D3/n, for CM15 n is
15). D3¼Q/(32982cl), where ‘c’ is the molar concentration of the
peptide (mol L1), and ‘l’ is the optical path length expressed
in cm.
Estimation of the secondary structure content of CM15 from
CD spectroscopic data
In order to compute the fractions of a-helices, b-sheets, turns
and unordered content of ligand-free and ligand-loaded forms41092 | RSC Adv., 2017, 7, 41091–41097of CM15, the DichroWeb online server was used.16 Taking into
consideration the disordered structure of CM15, reference data
set 7 was applied against the experimental CD data between
190–240 nm. In contrast to other reference sets, it contains
spectra of ve denatured proteins as well.16 The reference set 6
could also be used but it requires quality spectral data
measured down to 185 nm. Among the algorithms available on
DichroWeb for tting CD data to reference sets of proteins with
known secondary structure, the CDSSTR method yielded the
lowest (<0.03) and most consistent normalized root mean
square deviations (NRMSD) and, thus, was adopted here.17
Before secondary structure analysis, the experimental CD
spectra were smoothed with a convolution width of 17 using the
Means-Movement method (JASCO Spectra Analysis soware,
version 1.53.00).
Dynamic light scattering (DLS) analysis
DLS measurements were performed on a W130i instrument
(Avid Nano Ltd., High Wycombe, UK) with diode laser (660 nm)
and a photodiode detector at 20 C. Low volume disposable
cuvettes having a 1 cm path length were used (UVette, Eppen-
dorf Austria GmbH). Diﬀerent amount of drugs, dyes and
heparin were added to 53 mL CM15 sample (30.5 mM) which
then diluted to a nal volume of 80 mL (20 mM CM15) with the
same buﬀer used for the CD spectroscopic measurements. The
rst data acquirement was performed 120 s aer addition of the
ligands to the peptide solution to ensure the homogeneity of the
sample. The time-dependent autocorrelation functions were
measured for 10 seconds, repeated 10 times and the average
distributions were reported. The average and the standard
deviation values of the sizes corresponding to the peak of
interest in each of these distributions represent the apparent
hydrodynamic diameter and the experimental error for each
sample, respectively. DLS data were processed with the iSize 3.0
soware (Avid Nano Ltd., High Wycombe, UK).
Peptide synthesis, purication and characterization
See the ESI.†
Computational details
See the ESI.†
Results and discussion
Chiroptical evaluation of the induced folding of CM15
Circular dichroism (CD) spectroscopy is an inherently sensitive,
non-destructive tool for the conformational analysis of peptides
and proteins.18,19 The far-UV CD curve recorded in buﬀer solu-
tion indicates that the structure of CM15 is intrinsically disor-
dered (Fig. 1A). The spectrum is dominated by a sole negative
band at around 199–200 nm which is typical of highly dynamic
conformational ensembles.18 Furthermore, there is no shoulder
in the 210–230 nm region which also refers to the lack of
dominant secondary structural elements. In full concordance
with this qualitative assessment, quantitative evaluation of the
CD data shows the decisive contribution of the disordered stateThis journal is © The Royal Society of Chemistry 2017
Fig. 1 (Panel ‘A’) Far-UV CD spectrum of 30 mM CM15 in buﬀer and in
triﬂuoroethanol. (Panel ‘B’) Far-UV CD spectra of 23 mMCM15measured
at increasing concentrations of heparin in the sample solution (10 mM
potassium phosphate buﬀer at pH 7.3, 50 mM Na2SO4, 25 C).
Paper RSC Advances(Table 1). However, in TFE, which provides a strong dehydration
force allowing the backbone to collapse into a self-H-bonded
form, profound spectral changes occur (Fig. 1A). The negative
band is replaced by an intense couplet consisting of a longer
wavelength negative and a shorter wavelength positive peak thatTable 1 Estimation of the percentual secondary structure content of fre
ﬁnal concentration of the peptide at the end of the titrations (dilution eﬀe
used for the secondary structure analysis performed with the DichroW
normalized root mean square deviation
[CM15] (mM) [Ligand] (mM) a-H
CM15 in TFE 30 — 77
CM15 in buﬀer 23 — 4
+Heparin 23 (16) 32 43
CM15 in buﬀer 40 — 4
+Congo red 39 (32) 80 19
CM15 in buﬀer 39 — 5
+Trypan blue 39 (28) 100 24
CM15 in buﬀer 39 — 4
+Suramin 39 (36) 45 15
CM15 in buﬀer 27 — 5
Pamoic acid 27 (14) 136 21
This journal is © The Royal Society of Chemistry 2017correspond to the p–p* exciton components of the peptide
bonds. In addition, there is an unresolved minimum at about
222 nm allied to the n–p* transition of the amide chromo-
phores. All of these spectral features complemented with the
quantitative analysis refer to the a-helical folding of CM15
(Table 1).
It is well documented that besides membrane binding and
TFE, polyanionic biopolymers such as sulfated glycosamino-
glycans (e.g., heparin, heparan sulfate) can also provoke the
folding of AMPs.20–22 In line with these reports, our CD spec-
troscopic results verify that albeit in a less extent to that
observed in TFE, the coil-to-helix transition of CM15 can be
successfully induced by heparin (Fig. 1B and Table 1). For the
rst time, this communication demonstrates that similar
structural rearrangement can also be prompted by pharma-
ceutical drugs and synthetic dyes possessing acidic functional
groups (Scheme 1). Sequential addition of drugs (suramin,
pamoic acid, cromolyn) as well as sulfonated dyes (Congo red,
trypan blue) substantially altered the disorder-associated CD
prole of CM15 (Fig. 2 and 3). The broad negative band is
gradually converted into a polyphasic curve displaying two
negative and a positive extremum above and below 200 nm,
respectively. These spectral transformations occurred promptly
aer addition of the ligands and exhibited no time dependence.
In relation to the a-helical pattern measured in TFE, the nega-
tive–positive couplets are less intense and the lmax values are
red shied (Fig. 2 and 3). Additionally, the spectral positions of
the isodichroic (zero crossover) points are also at higher wave-
lengths than that displayed in Fig. 1A (202 nm) and they are
shied to longer wavelengths during the titrations (ESI
Fig. S1†). The smallest shi was observed with heparin followed
by trypan blue and Congo red. Of note, the classical coil# helix
equilibrium generates a family of CD spectra with an iso-
dichroic point near 203 nm.18,23 In contrast, the isodichroic
points of coil# b-sheet transitions are at longer wavelengths
ranging between 208 and 215 nm.24,25 Consideration of these
results refers to the ligand binding induced disorder-to-order
structural transition of CM15 which involves more than two
conformational states. It seems that besides the a-helix, ligande and ligand-loaded forms of CM15. Values in parentheses denote the
ct). Far-UV CD spectral data between 190–240 nm (D3/residues) were
eb application (CDSSTR program with reference data set 7). NRMSD:
elix b-Sheet Turn Unordered NRMSD
7 7 9 0.004
13 9 74 0.017
12 15 30 0.024
14 9 73 0.012
26 17 37 0.021
13 10 72 0.017
20 19 36 0.017
12 9 74 0.016
26 21 37 0.019
13 9 72 0.018
26 17 37 0.027
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Scheme 1 Chemical structures of folding inducer small molecules
used in this study.
Fig. 2 Far-UV CD spectroscopic changes of CM15 (39 mM) measured
upon consecutive increase of the concentrations of sulfonated azo
dyes and the antiparasitic drug suramin in the sample solution (10 mM
potassium phosphate buﬀer at pH 7.3, 50 mM Na2SO4, 25 C). Thin
lines are smoothed versions of the CD curves obtained at the highest
concentration of the ligands.
RSC Advances Papermolecules also aﬀect the percentage of additional structural
elements such as b-sheets and turns. That is supported by the
estimation of the secondary content of ligand-loaded CM15
(Table 1). At the cost of the unstructured component, the a-
helical fraction multiplied by a factor of 4–5 but the b-sheet and
turn content rose signicantly as well. Taking into account the
CD changes in the function of the ligand/peptide molar ratio,
suramin was the most eﬀective folding inducer whilst trypan
blue and Congo red increased the helix content to the greatest
extent. In marked contrast to heparin which le the b-sheet
fraction unaltered, all compounds raised its proportion (Table
1). Since the heparin chain lacks aromatic rings, this structural
motif may be responsible for the sheet promoting activity of the
small molecules.
It is to be noted that at high pamoic acid concentrations, two
negative CD peaks are displayed at 227 and 236 nm in the strong
UV absorption band of the naphthyl units (Fig. 3). Most likely,
these signals are not of peptide origin but allied to the asym-
metrically perturbed p–p* transitions of pamoic acid. As such,
these are induced (extrinsic) CD eﬀects associated to the inter-
action between the chiral peptide and the achiral ligand.2641094 | RSC Adv., 2017, 7, 41091–41097Encoded by its structure, pamoic acid has a pronounced
tendency to conformational enantiomerism induced by asym-
metric hosts.27,28 Interestingly, considered as a pharmacologi-
cally inactive constituent, pamoic acid has long been used in
several drug formulations as pamoate salt. It has been dis-
closed, however, that it is a potent agonist of the human G-
protein coupled receptor 35.29,30
CD spectroscopic changes were utilized to estimate the
binding aﬃnity and stoichiometry of the folding inducer
agents. Upon successive addition of the ligands, the original CD
curve gradually transformed including the appearance of a zero
crossing point at shorter wavelengths which then shied
bathochromically during the titration (Fig. 1–3, ESI Fig. S1†).
However, no further shi was observed at the end of the titra-
tions at high ligand/peptide molar ratios. The measure of the
shi in wavenumber was calculated as the arithmetic diﬀerence
between the local maximum of the native peptide at 188 nm
(53 191 cm1) and the actual position of the crossing point at
increasing concentrations of the ligand. It is a better approach
than using CD intensity changes since rising the concentrationThis journal is © The Royal Society of Chemistry 2017
Fig. 3 Representative CD curves of CM15 (27 and 30 mM) measured
upon consecutive increase of the concentration of pamoic acid and
the antiallergic drug cromolyn in the sample solution (10 mM potas-
sium phosphate buﬀer at pH 7.3, 50 mM Na2SO4, 25 C). Thin line
(orange) is the smoothed version of the CD curve obtained at the
highest concentration of pamoic acid.
Table 2 Ligand–CM15 binding parameters (Kd and the Hill coeﬃcient)
as derived from non-linear regression analysis of the CD spectroscopic
data (see data ﬁtting results in ESI Fig. S2)
Ligand Kd (mM) h R
2
Heparin 13.3 (0.2) 2.9 (0.1) 0.9974
Suramin 16.2 (0.5) 2.1 (0.1) 0.9968
Pamoic acid 85.8 (3.6) 2.8 (0.3) 0.9917
Congo red 42.2 (0.4) 4.0 (0.1) 0.9990
Trypan blue 49.6 (0.7) 2.8 (0.1) 0.9982
Paper RSC Advancesof UV-active ligands in the sample solution progressively dete-
riorates the signal-to-noise ratio resulting in less reliable data
points for the estimation of the binding parameters. Non-linear
regression analysis of the shi values plotted against the
concentrations of the inducers gave rise to a sigmoidal curve in
each case suggesting cooperative binding interactions (ESI
Fig. S2†). The Hill coeﬃcients (h) indicate the formation of
multimeric complexes where 2–4 ligand molecules are accom-
modated to a peptide chain (Table 2). According to the apparent
Kd values, suramin binds most tightly to CM15 followed by the
azo dyes and pamoic acid. Importantly, the CM15 aﬃnity of
suramin and heparin is equally strong which could be due to
the high degree of sulfation and thus the heparin-mimicking
ability of this drug as reported previously in the literature.31–34
The development of suramin was based on earlier observations
on the trypanocidal activity of related polysulfonated dyes such
as trypan blue.35,36 As a highly promiscuous drug showing
antiprotozoal, antihelminthic, antiviral and anticancer activi-
ties, suramin aﬀects the function of diverse range of receptors,
growth factors and enzymes.34,35 Interestingly, many of them
possess ID regions raising the possibility that this drug may
alter protein functions by inducing disorder-to-orderThis journal is © The Royal Society of Chemistry 2017conformational transitions (ESI Table S2†). Similarly to sur-
amin, some protein targets of Congo red (ESI Table S3†),
pamoic acid (ESI Table S4†) and even cromolyn (ESI Table S5†)
contain ID sequences as well.
Distinctly from the other compounds, the antiallergic drug
cromolyn failed to transform the monophasic CD prole. It
diminished the amplitude of the negative peak but did not
produce appreciable changes above 210 nm (Fig. 3). As seen
during the initial phase of ligand–CM15 titrations, intensity
decrease of the negative band is the prelude to further profound
spectral modications. Accordingly, this suggests that cromolyn
triggers the transition of CM15 to a more ordered conformation.
Presumably due to steric reasons (see below), this drug possesses
a weaker folding activity and thus its structure ordering eﬀect lags
behind that of the pamoic acid and sulfonated compounds. It is
to be noted that closely resembling CD spectroscopic changes
were witnessed upon titration of the natively unfolded a-synu-
clein with DDT.37 In parallel with the increasing concentration of
the pesticide, the single negative CD band lost intensity which
was considered as the sign of a disordered-to-misfolded confor-
mational shi of the protein.
In analogy with heparin–AMP complexes, coulombic inter-
actions and intermolecular H-bonds between lysine residues of
CM15 and anionic/hydroxylic groups of the ligands may be
decisive in the folding by screening intra-chain electrostatic
repulsions. In this regard, the sulfonate and carboxylate groups
seem to be equipotent since pamoic acid showed similar helix
promoting ability to that of trypan blue and Congo red (Table 1).
The aromatic units connected by single bonds may serve as
a semi-rigid framework holding the anionic groups in suitable
positions for binding to the peptide. Moreover, upon accom-
modation of the ligands, the water molecules along the peptide
chain are replaced by aromatic moieties. Therefore, the local
dielectric constant between the positively charged residues
declines which may also contribute to the stabilization of the
adducts. The chemical constitution of cromolyn allows much
larger conformational freedom than that of pamoic acid or the
sulfonated inducers (Scheme 1) which may account by for its
impaired folding promoting capability.Ligand-induced aggregate formation monitored by dynamic
light scattering (DLS) method
DLS measurements were conducted to detect the formation of
molecular aggregates and to determine their sizes. The experi-
ments were designed to simulate the conditions of the CDRSC Adv., 2017, 7, 41091–41097 | 41095
RSC Advances Papertitrations employing similar peptide and ligand concentrations.
No particle formation could be detected in the 20 mM sample
solution of the native CM15. The same result was obtained aer
addition of the rst aliquot of stock solutions setting 1 : 2
ligand : peptide molar ratio. However, upon increase this value
to 1 : 1 and above, large aggregates, except for pamoic acid,
appeared with a hydrodynamic radius of 1000 nm (ESI Table
S6†). This nding can be explained by the mutual charge
neutralization within the complexes composed from the cationic
CM15 and its anionic partners. As a consequence, the resulting
adducts become less hydrophilic and are prone to aqueous
aggregation. According to the largest values of the polydispersity
index, the particle size distribution is most heterogeneous at
2 : 1 ligand : CM15 ratio. Further rising of the ligand concen-
tration decreases the broadness of the size distribution. Pamoic
acid triggered less eﬀectively the aggregation process that might
be related to its lowest CM15 aﬃnity (Table 2).Computational studies
To provide a molecular level insight into the potential interac-
tions manifesting in the ligand–CM15 complexes, semi-
empirical calculations were performed employing the PM3MM
method. For all the ve ligands several relative conformations
were considered and the most stable ones were analyzed in
detail. The obtained lowest energy structures all show strong
interactions with the lysine side chains. All small molecules
form salt bridges, H-bonds or, in the case of pamoic acid,
cation–p interaction with at least three lysine residues (ESI
Table S7†). The disposition of the lysine side chains seems also
important, as residues from the N-terminal, from the middle of
the sequence, as well as from the C-terminal are involved.
Accordingly, Congo red, cromolyn, pamoic acid form salt
bridges with Lys1, Lys6 and Lys13. Note that for pamoic acid,
Lys6 coordinates on one of the naphthyl groups forming a less
common cation–p interaction. For all molecules studied here,
except pamoic acid, intermolecular p–p stacking with either
Trp2 or Phe5 is present stabilizing further the lowest energy
structures. Themost intermolecular salt bridges and H-bonds, 8
altogether, can be observed for the suramin–CM15 complex,
with the participation of all lysines. The cationic amino and the
anionic sulfonate groups of lysines and suramin form a salt
bridge network (ESI Fig. S3†), which may give an extra stabili-
zation to the complex, as supported by the highest aﬃnity
observed for this ligand (Table 2). In summary, the theoretical
calculations indicate that all the ligands could span their
negatively charged groups along the CM15 chain enabling
formation of a salt-bridge with at least one lysine from the N-,
Lys1 or Lys3, one lysine from the C-terminal, Lys13, as well as
one from the middle of the sequence, i.e. either Lys6 or Lys7.
Forming a favorable interaction simultaneously with a Lys
from these three positions seems a prerequisite to induce
folding of CM15. This is also supported by those optimized
structures where the small organic molecule is located only on
one half of CM15. For these instances, the region of CM15
which does not interact with the small molecule adopts
a random conformation (ESI Fig. S4†).41096 | RSC Adv., 2017, 7, 41091–41097Overall, the rst experimental evidence on the folding
promoting activity of therapeutic drugs communicated here
suggests a potential strategy for targeting ID sequences in
peptides and proteins. The structural ordering eﬀect of small
molecules on disordered regions would prevent their inter-
action with natural peptide/protein partners thereby allowing
the modulation of various activation and signaling path-
ways.38,39 On the other hand, the recognition of such property
may help to better understand therapeutic actions and
adverse eﬀects of pharmaceutical agents. The identication of
ID target sequences of approved drugs may expand their
therapeutic repertoire beyond the conventional indications.
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Peptide synthesis and purification 
CM15 was produced on solid phase (Fmoc-Rink Amide MBHA, capacity = 0.67 mmol/g) 
resin in an automated peptide synthesizer (Syro-I, Biotage) using standard Fmoc/tBu strategy 
with DIC/HOBt coupling reagents. Peptide was cleaved from the resin with TFA/H2O/TIS 
(9.5 : 2.5 : 2.5 v/v) mixture (2 hrs, RT). After filtration the compound was precipitated in cold 
diethyl ether, centrifuged (4000 rpm, 5 min) and freeze-dried from water. Crude product was 
purified by RP-HPLC on a semipreparative C-18 Phenomenex Jupiter column (250 × 10 mm) 
using gradient elution, consisted of 0.1% TFA in water (eluent A) and 0.1% TFA in 
acetonitrile/water = 80/20 (v/v) (eluent B).  
 
Peptide characterization 
Purified CM15 was analysed by RP-HPLC on an analytical C-18 Zorbax (150 × 4.4 mm) 
column using gradient elution with the above mentioned eluent A and B (flow rate was 1 
mL/min, gradient was 5-100 B%, 20 min, UV detection at 220 nm).  
Molecular mass of the peptide was determined by using a Bruker Esquire 3000+ ESI mass 
spectrometer.  Peptide samples were dissolved in a mixture of acetonitrile/water = 1/1 (v/v) 
containing 0.1% acetic acid and introduced by a syringe pump with a flow rate of 10 μL/min. 
The peptide content was determined by amino acid analysis using a Sykam Amino Acid 
S433H analyser equipped with an ion-exchange separation column and postcolumn 
derivatization. Prior to analysis, samples were hydrolysed with 6 M HCl in sealed and 
evacuated tubes at 110 °C for 24 h. For post-column derivatization the ninhydrin-method was 
used. 
 
peptide	 sequence	 Za	
	
Mav	b	
calcd/found	
Rt	c	
(min)	
peptide	
content	e	%	
CM15  KWKLFKKIGAVLKVL  +6  1770.3/1770.4  13.6  52 
C‐terminus of the peptides was amidated.
 a Z: net charge at neutral pH. Calculated by the number of (K+R)‐(E+D). Positive charge at the N‐terminus 
increases Z by 1 unit.  
b
 Measured average molecular mass by Bruker Esquire 3000+ ESI‐MS.  
c
Analytical RP‐HPLC, gradient: 5% B, 5 min.; 5‐100% B, 20 min.  
d Peptide content was determined by amino acid analysis using freeze‐dried final product.  
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Computational details 
To support the experimental investigations with a molecular level insight into the potential 
interactions underlying the experienced conformational transitions, quantum chemical 
calculations were performed. All theoretical computations were conducted using the Gaussian 
09 (G09) software package 1. Graphical representation of the structures were created using 
Pymol (The PyMol Molecular Graphics System, DeLano Scientific, Palo Alto, CA). 
To investigate interaction of CM15 in helical conformation with the studied negatively 
charged compounds, initial models were built as follows. Helical starting structure of CM15 
was taken from an NMR experiment.2 All drug and dye molecules (suramin, pamoic acid, 
cromolyn, Congo red, trypan blue) were built using their solution phase, deprotonated forms, 
where the sulfonate and carboxylate groups consequently possess a negative charge. Initial 
structures of these compounds were optimized at the semi-empirical level, using the PM3MM 
method. PM3MM was developed from PM3 to include molecular mechanics correction for 
amide linkage present in peptides.3 The semi-empirical approach was chosen as it provides 
fast and efficient insight into the molecular level interactions with reasonable accuracy, 
without the cumbersome parametrization procedure required for in depth molecular dynamics 
simulations, a study beyond our current focus. Furthermore, the small molecule-peptide 
complexes are large molecular systems, up to 405 atoms, consequently preventing efficient 
use of higher quantum chemical methods, such as ab initio or density functional theory 
techniques. 
All complexes were optimized starting from 3 different relative positions of the CM15 helix 
and the addressed negatively charged compound, requiring a total of 15 different calculations. 
These all resulted in optimized structures except two positions for suramin and one for trypan 
blue complexes. The latter ones were subject of several optimization attempts, but failed to 
reach full convergence. Presented structures were chosen from the pool of three different 
binding modes based on their relative energies as well as on the quantity and quality of the 
intermolecular salt-bridges, hydrogen bonds, and stacking interactions. 
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Protein Name Disordered Sequence DisProt ID 
Eukaryotic peptide chain release factor 
subunit 1 (H. sapiens) 423EYQGGDDEFFDLDDY434 DP00310 
Ribonucleoside-diphosphate reductase 
M2 subunit (M.musculus) 
353NISLEGKTNFFEKRVGEYQ
RMGVMSNSTENSFTLDADF3
83 
DP00462 
DnaK suppressor protein (E. coli) 17IAGVEPYQEKPGEEYMN33 DP00414 
IIβ Phosphatidylinositol  phosphate  
kinase (H. sapiens) 
220STVAREASDKEKAKDLPT
FKDNDFLNEGQKL250 
DP00054 
Thymidylate synthase (H. sapiens) 107KIWDANGSRDFLDSLGFSTREE128 
DP00073 
DNA topoisomerase 1 (H. sapiens) 
175KPKNKDKDKKVPEPDNK
KKKPKKEEEQKWKWWEEE
RYPEG214 
DP00075 
SHC-transforming protein 1 
(H. sapiens) 
127GQLGGEEWTRHGSFVNKP
TRGWLHP149 
DP00154 
Cyclin-H (H. sapiens) 288NVITKKRKGYEDDDYVSKKSKHEEEEWTDDDLVESL323 
DP00307 
Cbp/p300-interacting transactivator 2 
(H. sapiens) 
220TDFIDEEVLMSLVIEMGLD
RIKELPELWLGQNEFDFMTD
FVCKQQPSRVS269 
DP00356 
Histo-blood group ABO system 
transferase (H. sapiens) 179KRWQDVSMRRMEMISD194 DP00339 
Alcohol sulfotransferase (H. sapiens) 13WDTYEDDISEISQK26 DP00404 
Ras-related protein Ral-A (H. sapiens) 72QEDYAAIRDNYF83 DP00581 
60S acidic ribosomal protein P2 (H. 
sapiens) 102SEESDDDMGFGLFD115 DP00793 
Small heat shock protein HSP16.5 (M. 
jannaschii) 
1MFGRDPFDSLFERMFKEFF
ATPMTGTTMIQSS32 
DP00067 
DNA gyrase inhibitor YacG (E. coli) 40WAAEEKRIPSSGDLSESDDWSEEPKQ65 
DP00202 
Calcyclin-binding protein 
(M.musculus) 
178EKPSYDTEADPSEGLMNV
LKKIYEDGDDDMKRTINKA
WVESREKQAREDTEF229
DP00226 
 
 
Supplementary Table 1 
Selected examples for experimentally verified, CM15-like disordered sequences consisting of 
charged (red) as well as aromatic residues (bold). Data were obtained from the DisProt 
database at http://www.disprot.org/.   
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Target protein Length (a.a.) 
Disorder 
(%) 
UniProt 
ID Refs. 
Protamine 1B (Rainbow trout) 33 100 P02326 4 
Basic fibroblast growth factor (H. 
sapiens) 288 55.56 P09038 
5 
Insulin-like growth factor 1 
(H. sapiens) 195 51.28 P05019 
5 
N-lysine methyltransferase 
KMT5A (H. sapiens) 393 49.87 Q9NQR1 
6 
NAD+-dependent protein 
deacetylase sirtuin-1 
(H. sapiens) 
747 47.93 Q96EB6 7 
Histone-lysine N-
methyltransferase EHMT1 
(H. sapiens) 
1298 43.61 Q9H9B1 6 
M-phase inducer phosphatase 1 
(H. sapiens) 524 39.89 P30304 
8 
Interleukin-2 receptor α-subunit 
(H. sapiens) 272 38.97 P01589 
9 
Platelet-derived growth factor 
subunit B (H. sapiens) 241 33.20 P01127 
5 
Hepatitis B virus core protein 185 32.43 G9BNJ2 4 
Tyrosine-protein phosphatase 
non-receptor type 1 (H. sapiens) 435 27.82 P18031 
8 
Tyrosyl-DNA phosphodiesterase 
1 
(H. sapiens) 
608 27.47 Q9NUW8 10 
D2 dopamine receptor 
(H. sapiens) 443 27.31 P14416 
11 
Receptor-type tyrosine-protein 
phosphatase C (H. sapiens) 1304 27.07 P08575 
8 
Tyrosine-protein phosphatase 
YopH (Y. enterocolitica) 468 25.43 P15273 
8,12 
DNA topoisomerase 2 
(S. cerevisiae) 1428 25.00 P06786 
13 
Carcinoembryonic antigen-
related cell adhesion molecule 1 
(H. sapiens) 
526 24.52 P13688 14 
P2X2 purinoceptor 
(R. norvegicus) 472 22.25 P49653 
15,16 
Receptor-type tyrosine-protein 
phosphatase α (H. sapiens) 802 20.82 P18433 
8 
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Target protein Length (a.a.) 
Disorder 
(%) 
UniProt 
ID Refs. 
P2Y2 purinoceptor (H. sapiens) 377 20.16 P41231 17,18 
NAD+-dependent protein 
deacetylase sirtuin-1 
(H. sapiens) 
389 20.05 Q8IXJ6 7 
Protein kinase C type β 
(R. norvegicus) 671 18.93 P68403 
19 
Tumor necrosis factor-α 
(H. sapiens) 233 18.88 P01375 
20 
DNA polymerase α catalytic 
subunit (H. sapiens) 1462 18.67 P09884 
21 
Heat shock protein 104 
(S. cerevisiae) 908 16.52 P31539 
22 
P2X1 purinoceptor 
(R. norvegicus) 399 12.78 P47824 
15,17,23 
Epidermal growth factor receptor 
(H. sapiens) 1210 12.40 P00533 
24 
Dual specificity protein 
phosphatase 3 (H. sapiens) 185 11.89 P51452 
12 
Nuclear receptor subfamily 1 
group I member 2 (H. sapiens) 434 11.29 O75469 
25 
Complement control protein C3 
(Vaccinia virus) 263 9.51 P68638 
26 
     
Supplementary Table 2 
Disorder prediction results for various proteins found experimentally to be affected by 
suramin. The percentage of residues involved in predicted disordered regions of proteins is 
based on the corresponding MobiDB consensus score (http://mobidb.bio.unipd.it).27 
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Target protein Length (a.a.) 
Disorder 
(%) 
UniProt 
ID Refs. 
Microtubule-associated protein 
tau (H. sapiens) 758 89.45 P10636 
28,29 
α-Synuclein (H. sapiens) 140 41.43 P37840 30 
Eukaryotic peptide chain release 
factor GTP-binding subunit 
(S. cerevisiae) 
685 38.10 P05453 31,32 
Choline O-acetyltransferase 
(H. sapiens) 748 20.59 P28329 
33 
Dihydrofolate reductase type 2 
(E. coli) 78 20.51 P00383 
34 
PH domain leucine-rich repeat-
containing protein phosphatase 2 
(H. sapiens) 
1323 17.54 Q6ZVD8 35 
RecA (E. coli) 353 9.63 P0A7G6 36 
     
 
Supplementary Table 3 
Disorder prediction results for various proteins found experimentally to be affected by Congo 
red. The percentage of residues involved in predicted disordered regions of proteins is based 
on the corresponding MobiDB consensus score (http://mobidb.bio.unipd.it).27 
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Target protein Length(a.a.) 
Disorder 
(%) 
UniProt 
ID Refs. 
Tyrosine-protein phosphatase 
non-receptor type 1 (H. sapiens) 435 27.82 P18031 
37 
β-Arrestin-2 (H. sapiens) 409 19.07 P32121 38 
Receptor-type tyrosine-protein 
phosphatase F (H. sapiens) 1907 15.57 P10586 
37 
DNA polymerase β (H. sapiens) 335 9.85 P06746 39 
G-protein coupled receptor 35 
(H. sapiens) 309 9.06 Q9HC97 
38,40,41 
 
 
 
Supplementary Table 4 
Disorder prediction results for various proteins found experimentally to be affected by pamoic 
acid. The percentage of residues involved in predicted disordered regions of proteins is based 
on the corresponding MobiDB consensus score (http://mobidb.bio.unipd.it/).27 
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Target protein Length(a.a.) 
Disorder 
(%) 
UniProt 
ID Refs. 
β-Arrestin-2 (H. sapiens) 409 19.07 P32121 42 
Protein S100-A13 (H. sapiens) 98 18.37 Q99584 43 
Protein S100-B (Bos taurus) 92 17.39 P02638 43 
Protein S100-A13 (Bos taurus) 98 13.27 P79342 44 
Protein S100-A12 (Bos taurus) 92 10.87 P79105 44 
G-protein coupled receptor 35 
(H. sapiens) 309 9.06 Q9HC97 
41,45 
 
 
 
Supplementary Table 5 
Disorder prediction results for various proteins found experimentally to be affected by 
cromolyn. The percentage of residues involved in predicted disordered regions of proteins is 
based on the corresponding MobiDB consensus score (http://mobidb.bio.unipd.it/).27 
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Ligand:CM15 
molar ratio 
 
Heparin 
 
Dh           P.d. 
Suramin 
 
Dh          P.d. 
Congo red 
 
Dh        P.d. 
Pamoic acid 
 
Dh     P.d. 
1:2     –              –     –             – –       – –    – 
1:1 850 (±382)  45 1098 (±569) 52 799 (±441)  55 –    – 
2:1 1902 (±1416) 75 859 (±647)   75 1460 (±1033) 71 131 (±76)  58 
3:1 870 (±426)   49 1053 (±589)  57 1577 (±968)  61 370 (±188) 51 
4:1 1021 (±519) 51 1453 (±1016) 70 937 (±478)    51 335 (±261) 78 
5:1 819 (±436)   53 1477 (±532)   36 880 (±289)    33 427 (±282) 66 
     
 
 
 
Supplementary Table 6 
Polydispersity (P.d. in %) of ligand-CM15 samples and mean hydrodynamic diameter (Dh in 
nm) of the particles measured by DLS method.  
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Ligand Intermol. Salt bridges 
Intermol. 
H-bonds 
Intermol. 
π-interaction  
 No.a Residue No. Residues Residue Type  
Trypan blue 5 
Lys3, 
Lys6, 
Lys7, 
Lys13 
- - Trp2 Stacking,T-shaped  
Suramin 8 
Lys1, 
Lys3, 
Lys6, 
Lys7, 
Lys13 
1 Lys6 Phe5 Stacking,T-shaped  
Congo red 3 
Lys1, 
Lys6, 
Lys13, 
- - Phe5 Stacking,T-shaped  
Pamoic acid 2 
Lys1, 
Lys13, - - Lys6 Cation-π  
Cromolyn 2 
Lys1, 
Lys13, 
 
2 Lys6 Trp2 
Stacking, 
Edge-
edge 
 
a: Number of interactions found. 
 
 
 
Supplementary Table 7 
Assigned intermolecular interactions for the lowest energy complexes of the investigated 
small molecule-CM15 systems. 
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Supplementary Figure 4 
Structures of the small molecule-CM15 complexes obtained at the PM3MM level of theory. 
For all models the organic small molecules are represented by yellow sticks, whereas the 
CM15 molecules are as green sticks. The models are oriented with the N-terminal residue of 
CM15 located at the top of each panel. A, B: Two configurations of the trypan blue-CM15 
complex. A: The one which does not involve H-bonds between the ligand and lysine residues 
from both terminals (i.e. Lys13 in this particular case) cannot induce folding of the entire 
CM15 sequence, and thus the calculation optimized into a partially unfolded conformation. C: 
The most stable complex of Congo red and CM15. D: The most stable complex of cromolyn 
and CM15. E: The most stable complex of pamoic acid and CM15. 
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